Osteosarcoma Therapeutics Market Analysis
As per DelveInsight’s analysis, the Osteosarcoma therapeutic market in the 7MM was estimated to be USD 72.50 million in 2017 and is further expected to increase modestly in the forecast period 2020-30.
Worldwide, some of the key companies such as Eisai, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurora BioPharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech are actively engaged in producing desirable pipeline therapies.
For more details on Osteosarcoma Therapeutics Market, visit: https://www.delveinsight.com/blog/osteosarcoma-market-key-pharma-companies/
Osteosarcoma Treatment Market Analysis
Osteosarcomas are rare, yet are the leading cause of deaths due to cancer in the pediatric population. It is a high-grade malignancy of mesenchymal origins. They are the most frequent forms of primary bone tumors and account for approximately 20% of all the bone tumors. With the incident population of less than 2500 in the 7MM (the US, EU5 (the UK, Germany, France, Italy, and Spain), and Japan)in 2017, the rarity of Osteosarcomas makes its management quite bone-breaking.
To bridge the treatment gaps, many pharma, and biotech companies in the Osteosarcoma treatment market including EISAI LIMITED, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurorabiopharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech, among others are developing novel therapeutic strategies.
For more details on Osteosarcoma Treatment Market, visit: https://www.delveinsight.com/blog/osteosarcoma-treatment-market/
Biliary Atresia Market Analysis
In 2017, the total incident cases of Biliary Atresia in 7MM was 613. The incident cases in the United Kingdom and France were found to be 45 and 42 respectively (in 2017).
The market size of Biliary Atresia in 7MM in 2017 was USD 2.9 million, which is expected to increase further during the forecast period 2017-2030.
The key companies in the Biliary Atresia market include Albireo, Intercept Pharmaceuticals and others.
For more details, visit: https://www.delveinsight.com/report-store/biliary-atresia-market
Medical Marijuana Clinical Studies
Over the years the clinical research and trials conducted around marijuana have produced many noteworthy results and researchers have found them as a very significant treatment option. Worldwide numerous clinical trials are going to evaluate the safety, and effectiveness of medical marijuana for a number of diseases such as ChronicPain, Cachexia, Epilepsy, multiple sclerosis, Anxiety, and many others.
Apart from these, a significant number of studies are going on to access the impact of medical marijuana on Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Huntington’s Disease, Irritable Bowel Syndrome, Schizophrenia, Psychosis, Glaucoma, and so many others.
The key companies in the medical marijuana markets include Cannabics Pharmaceuticals, GSK, Tilray, GW Pharmaceuticals, OTSUKA PHARMACEUTICALS, Aurora Cannabis, Tetra Bio-Pharma, and many others.
For more details, visit: https://www.delveinsight.com/blog/medical-marijuana-clinical-trials/
Glioblastoma Multiforme Market Analysis
As per the DelveInsight's estimate the Glioblastoma Multiforme market is anticipated to veer forward with a CAGR of 8.25% in the 7MM (i.e. the United States, EU5 (the UK, Germany, Spain, Italy, and France) and Japan).
Some of the key companies, such as Bristol Myers Squibb, VBL Therapeutics, DelMar Pharmaceuticals, VBI Vaccines, Diffusion Pharmaceuticals, Ziopharma, Apogenix, DNAtrix, Immunomic Therapeutics, Kazia Therapeutics, Medicenna Therapeutics, among others, are investing their funds, time, and efforts in accelerating the Glioblastoma multiforme market.
For more detailed information on Glioblastoma Multiforme market, visit: https://www.delveinsight.com/blog/glioblastoma-multiforme-market/
Glioblastoma Multiforme Treatment Market
Glioblastoma Multiforme are rare tumors with a global incidence of less than 10 per 100,000 people. As per the Delveinsight analysis, the total Glioblastoma multiforme incident population in the 7MM (i.e. the United States, EU5 (the United Kingdom, Germany, Italy, Spain, and France) and Japan) was estimated to be around 2900 in 2017, which is expected to further increase during the forecast period 2017-2030.
To address Unmet needs in the Glioblastoma Multiforme treatment market, several pharmaceutical companies such as Bristol-Myers Squibb, DelMar Pharmaceuticals, AbbVie, Aivita Biomedical, Diffusion Pharmaceuticals, MedImmune, DNAtrix, Apogenix, Kazia Therapeutics, Medicenna Therapeutics, and many others are running clinical trials, investigating their candidates in different stages of clinical development.
To read more on Glioblastoma Multiforme Treatment Market, visit:
https://www.delveinsight.com/blog/glioblastoma-multiforme-treatment-market/
Peripheral Nerve Injury Market
Every year, around 1.35 million people die due to vehicular or road accidents. Road crashes are also the most common cause of peripheral nerve injury (PNI), affecting the brachial BP or the radial, fibular, or sciatic nerves, typically in young motorcycle riders.
The Peripheral Nerve Injury incidence in 2017 in the 7MM (i.e. The United States, EU5 (the United Kingdom, Spain, Germany, Italy, and France) and Japan) was found to be 3,889,176. The Peripheral Nerve Injury incidence rate for the US was reported to be the highest in the 7MM, with over 1.5 million cases in 2017.
Some of the key companies involved in developing therapies for the Peripheral nerve injury includes Neuraptive Therapeutics, Silk Biomaterials, and Orthocell Ltd.
For more details on Peripheral Nerve Injury Market, visit:
https://www.delveinsight.com/blog/peripheral-nerve-injury-market/
Sjogren's Syndrome Market
In 2017, the total prevalent cases of Sjogren’s Syndrome in 7MM were 3,179,223. The prevalent cases in Spain was found to be 197,008 in 2017.
The market size of Sjogren’s Syndrome in 7MM in 2017 was USD 1,699.8 Million, which is expected to increase further during the forecast period 2017-2030.
The key companies involved in developing therapies for Sjogren’s Syndrome include Novartis, MorphoSys, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb and many others.
For more details visit: https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
Hypofibrinogenemia Market
The market size of Hypofibrinogenemia in the 7MM was USD 161.5 Million in 2017, which is expected to increase further during the forecast period 2017-2030.
In 2017, the total prevalent population of Hypofibrinogenemia in the 7MM was 11,084. The prevalent population of Hypofibrinogenemia in Spain was found to be 493.
Some of the key companies involved in developing therapies for Hypofibrinogenemia includes Biotest, CSL Behring, Octapharma, LFB Biomedicaments and many others.
For more detailed information on Hypofibrinogenemia market, visit: https://www.delveinsight.com/report-store/hypofibrinogenemia-market
Rheumatoid Arthritis (RA) Market Analysis
In 2017, the total prevalent cases of Rheumatoid Arthritis in 7MM was 4,356,793. The prevalent cases of Rheumatoid Arthritis in the United States were 1,333,290, while Germany had 836,101 prevalent cases in 2017.
The market size of Rheumatoid Arthritis in 7MM was USD 21.2 Billion in 2017.
Increase in the prevalence population of Rheumatoid Arthritis, increase in geriatric population and rich emerging pipeline are some of the key factors expected to drive the Rheumatoid Arthritis market in the coming years.
Some of the key players in the Rheumatoid Arthritis market include GlaxoSmithKline, Gilead, Galapagos NV, R-Pharm, Mesoblast, UCB Pharma/PRA HEALTH SCIENCES, Izana Bioscience/Takeda, Abivax S.A., Hope Biosciences and Genosco (Oscotec).
For more details, visit: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
Schizophrenia Market Analysis
In 2017, the total prevalent population of Schizophrenia in the 7MM was 5,616,463. Among 7MM, the EU5 countries occupied 22.47% of the patient pool in 2017.
The market size of Schizophrenia in 7MM was USD 6,066.97 million in 2017.
The key companies in the Schizophrenia market include Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, Sunovion/PsychoGenics, Acadia Pharmaceuticals, Forum Pharmaceuticals, BioXcel Therapeutics, Avineuro Pharmaceuticals, Alkermes, Concert Pharmaceuticals, Newron Pharmaceuticals, Corcept Therapeutics, Merck, and Celon Pharma.
For more details, visit: https://www.delveinsight.com/report-store/schizophrenia-market
Epidermolysis Bullosa Market Analysis
In 2017, the total prevalent population of Epidermolysis Bullosa in 7MM was 41,509. The prevalent cases of Epidermolysis Bullosa in the United States was 26,104 in 2017, while the United Kingdom and Germany had 5,037 and 4,919 prevalent cases respectively.
The market size of Epidermolysis Bullosa in 7MM USD 2,283.40 million in 2017.
The key players in the Epidermolysis Bullosa Market includes Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Menlo Therapeutics and Phoenix Tissue Repair.
For more detailed information on Epidermolysis Bullosa Market, visit:
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Osteosarcoma Market Analysis
In 2017, the total incident population of Osteosarcoma in 7MM was 2,181. The incident cases of Osteosarcoma in the United States was found to be 1,141 in 2017.
The therapeutic market of Osteosarcoma in 7MM was found to be USD 72.50 million in 2017.
Robust pipeline, increase in incidence and more Immunotherapies into clinical trials are some of the key factors expected to drive the Osteosarcoma Market forward in the coming years.
The key players in the Osteosarcoma Market includes Bayer, Exelixis, Nektar Therapeutics, Eisai, Y-mAbs Therapeutics, GlaxoSmithKline, Novartis, Aadi Bioscience, Vaccinex, Inc., Eleison Pharmaceuticals, Aurora biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb and Cellestia Biotech.
For more detailed information on Osteosarcoma Market, visit:
https://www.delveinsight.com/report-store/osteosarcoma-market
Cervical Cancer Market
Cervical Cancer is the fourth most common type of cancer and the fourth leading cause of death in women.
As per DelveInsight, cervical cancer incidence by 2020 is estimated to be 43,712 in the 7MM.
Cervical Cancer Market is anticipated to increase with a modest CAGR of 16.9% for the study period of 2017-2030 in 7MM. Recent progress in the technology, emerging immunotherapies targeted therapies, and vaccines as monotherapy or in concomitance with chemos are expected to improve cervical cancer treatment landscape.
Several pharma companies are proactively exploring novel treatment options to treat cervical cancer. Some of the key companies in the cervical cancer market includes Regeneron, AstraZeneca, Iovance, Zeria Pharmaceutical, Seattle Genetics, Genmab, Agenus Bio, Roche, Akeso Biopharma, and Vaccibody.
For more details visit:
https://www.delveinsight.com/blog/cervical-cancer-market/
Telehealth Market
Telehealth has significantly improved healthcare related outcomes for secured and unsecured population in both developed and developing countries. Before the advent of Covid-19 pandemic, Telehealth was an unsung aspect of digital healthcare. However, during the pandemic, Telehealth has observed a massive growth, especially as face-to-face interactions between the patients and physicians have decreased dramatically. As remote working in healthcare is gaining traction, this digital feature is expected to register an upward growth trend in the coming years.
For more details, visit:
https://www.delveinsight.com/blog/drivers-and-barriers-of-telehealth/
d-barriers-of-telehealth/
Cervical Cancer Market
In 2017, the total prevalent population of Cervical Cancer in 7MM was 43,514. The prevalent cases of Cervical Cancer in the United States in 2017 was 32.07% of the total prevalent cases.
The therapeutic market of Cervical Cancer in the 7MM was found to be USD 330.59 million in 2017.
The key players in the Cervical Cancer Market includes Seattle Genetics, Genmab, AstraZeneca, Zeria Pharmaceutical, Regeneron Pharmaceutical, Sanofi, Advaxis, Iovance Biotherapeutics, Agenus, Roche, Akeso Biopharma, Vaccibody and Altor BioScience.
For more detailed information on Cervical Cancer Market, visit:
https://www.delveinsight.com/report-store/cervical-cancer-market
Retinal Vein Occlusion Market
In 2017, the total prevalent cases of Retinal Vein Occlusion in 7MM was 2,225,011. The total prevalent cases of Retinal Vein Occlusion in the United States was 1,124,718 in 2017.
The market size of Retinal Vein Occlusion in the 7MM was USD 2,127.70 Million in 2017.
The key players in the Retinal Vein Occlusion Market include Novartis Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics and The Emmes Company.
For more detailed information on Retinal Vein Occlusion Market, visit: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Mydriasis Market Analysis
In 2017, the diagnosed prevalent population of Mydriasis in the United States was 3,580,350. In the United States the Cataract Surgeries performed in the age-specific cases (70–79) in 2017 were 1,390,000.
The market size of Mydriasis in the seven major markets was USD 104.52 million in 2017.
Rising Geriatric population and cost-effectiveness of the Current Standard of Care are the key factors expected to drive the Mydriasis market forward in the coming years.
The key companies in the Mydriasis market include Ocuphire Pharma, Théa Laboratories, Omeros Corporation and others.
For more detailed information on Mydriasis market, visit:
https://www.delveinsight.com/report-store/mydriasis-market
Multiple Myeloma Market
In 2017, the total incident cases of Multiple Myeloma in 8MM was 85,971. The incident cases of Multiple Myeloma in the United States was found to be 30,271 in 2017.
The market size of Multiple Myeloma in 8MM was USD 14,111 million in 2017.
The key players in the Multiple Myeloma Market includes GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, AbbVie, Roche, ExCellThera, Takeda, Glenmark, Poseida Therapeutics, Amgen, Precision BioSciences, Juno Therapeutics, Molecular Partners AG, Cartesian Therapeutics, AstraZeneca, MorphoSys AG, I-Mab Biopharma and Chipscreen Biosciences.
For more detailed information on Multiple Myeloma Market, visit: https://www.delveinsight.com/report-store/multiple-myeloma-market
Chatbots To Assist Patients And Healthcare Providers
The chatbots are text or voice-based conversational software that connects users to the service provider to execute certain actions/query or to retrieve necessary information through mobile applications, websites, or telephone. In today’s highly competitive and advancing healthcare environment chatbots are playing a crucial role in the healthcare delivery system.
Chatbots in the healthcare domain offer advantages to both service providers and patients. Providing medication information or reminders to patients, scheduling appointments, reducing workload, 24×7 operational capabilities, and cost-effectiveness are some of the key benefits of chatbots in the healthcare delivery system.
Advancement in technology, rise in chronic disease, round-the-clock service demand from patients and reduced operating costs for healthcare providers, are some of the key factors which are expected to drive the healthcare chatbots market forward in the coming years.
Some of the leading companies in the healthcare chatbots market include Florence, Babylon Health, Ada Health, Sensely, Safedrugbot, GYANT, Cancer Chatbot and many others.
For more details, visit:
https://www.delveinsight.com/blog/healthcare-chatbots/
Joined Feb 2020
